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Abstract: Objective: This review aims to arm readers with a deep understanding of pharmacokinetics of digoxin. 
Data Sources: Pharmacology and pharmacokinetic references texts, and peer reviewed medical journal manuscripts   
indexed on Medline included based on currency, accuracy and appropriateness. 
Results: Physiologic changes and disease associated with aging have an impact on pharmacokinetics and pharmacody-
namics of medications. Altered drug response and increased adverse reactions are common amongst the elderly. The  
narrow therapeutic index of digoxin and pharmacokinetic changes associated with aging increases the risk of toxicity. In 
the aging population, a number of factors combine to increase the risk, severity and likelihood of hospitalisation or death 
due to adverse drug effects:  
• changes to absorption, distribution, metabolism and excretion,  
• increased susceptibility to drug sensitivity,  
• co-existing pathology,  
• polypharmacy.  
Conclusion: A thorough understanding of digoxin pharmacokinetics in the older person is essential for improved   
therapeutic outcomes, improved compliance, reduced morbidity and improved quality of life. 
Keywords: Ageing, digoxin, pharmacokinetics, toxicity.  
INTRODUCTION 
 Pharmacokinetics examines the absorption, distribution, 
metabolism and excretion (ADME) of drugs, and the associ-
ated toxic or therapeutic responses [1-4]. Pharmacokinetics 
includes applications in bioavailability, variations due to 
physiological or pathological conditions, disease related dose 
adjustment, drug interactions, and customisation of drug 
dosage regimes [1-4]. An important division of pharmacol-
ogy closely related to pharmacokinetics is the study of fac-
tors affecting bioavailability to optimise therapeutic activity 
of drugs, known as biopharmaceutics [1, 2].  
  The underlying principle of pharmacokinetics and the 
focus of this discussion is consistent with the philosophy of 
Paracelsus (medieval alchemist) who suggested that “only 
the dose makes a thing not a poison” [1]. Within a window,  
a specific drug will offer therapeutic benefit and outside   
that window there will either be no therapeutic benefit or tox-
icity. The narrow therapeutic range of digoxin means that  
small variations in blood concentration may easily result in  
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toxic or sub therapeutic concentrations. To maintain concen-
trations within the therapeutic range requires consistent 
bioavailability and careful management of factors that may 
influence bioavailability. Thus the aging body presents varia-
tions to physiological and pathological status that can have  
a profound influence on bioavailability, pharmacological 
response, drug sensitivity and drug interactions. The changes 
associated with the elderly demand more astute medication 
management and monitoring.  
DRUG RESPONSE AND AGING 
  Physiologic changes and disease occur with aging and 
can affect drug pharmacokinetics in older persons [5, 6]. 
Older people can not only have altered function but they can 
also have altered responses to the drugs themselves relating 
to mechanical responses, receptor mechanisms, homeostatic 
changes and CNS function [7,8]. The high prevalence of 
disease in the elderly also results in a higher use of medica-
tions and the incidence of adverse drug effects correlates 
with age [9]. As many as 20% of hospitalisations in the eld-
erly are due to adverse effects of medications and 18% of 
hospital deaths in the elderly are associated with adverse 
effects of medications [9]. Perhaps the most important con-
sideration for drug use and response in the elderly is that 
there is greater heterogeneity in older populations than Pharmacokinetic Considerations for Digoxin in Older People  The Open Cardiovascular Medicine Journal, 2011, Volume 5    131 
younger people which means not only that there is signifi-
cant variation is disease states but also significant variations 
in responses to medications [10]. No doubt the under repre-
sentation of the elderly in pharmaceutical clinical trials con-
tributes to adverse effects in this cohort [9]. 
With aging comes:  
•  Altered absorption (eg. slower gut or transdermal absorp-
tion). 
•  Changed bioavailability (eg. increased for highly extracted 
drugs). 
•  Changed biodistribution (eg. more extensive for lipid 
soluble drugs and less extensive in water soluble drugs). 
•  Altered metabolism (eg. cytochrome based metabolism in 
the liver). 
•  Altered elimination (eg. slower renal excretion) [5, 6, 11]. 
  Irrespective of age related changes to absorption, distri-
bution, metabolism and excretion, older people also demon-
strate an increased sensitivity to many drugs due to comor-
bidity and polypharmacy [7]. The elderly are at higher risk 
of an adverse drug effect, have increased severity of effects, 
are less likely to report adverse effects and are more likely to 
be hospitalised or die due to adverse drug effects [9].  
  Pharmacokinetic changes due to age related physiologi-
cal variations demand attention toward dose requirements   
in older people [5, 6]. Nonetheless, it is often difficult to 
differentiate pharmacokinetic changes resulting from aging 
from coexisting environmental influences, disease and other 
medications [12]. Consequently, drug therapy is difficult to 
predict in an older person so medication should be started at 
a low dose and increased this slowly with close monitoring 
of benefits and adverse effects [12, 13]. 
Absorption 
  With increasing age the amount of saliva produced is 
often reduced and this can reduce the rate of drug absorption 
by influencing the gastric pH [2, 8]. Furthermore, older peo-
ple have reduced gastric acid secretion and reduced acidity 
(increased pH) which can delay dissolution of oral medica-
tions [2, 3, 8, 9]. This is exacerbated by delayed gastric 
empty due to reduced peristaltic force that reduces the me-
chanical influences on medication mixing with gastric juices 
[3, 8, 9]. The surface area for drug absorption is also de-
creased in aging due to intestinal atrophy which, combined 
with reduced concentration gradient due to the poorer blood 
flow, inhibit passive diffusion of drugs into the blood stream 
further delaying absorption rate [8]. While this does not 
change the total absorption itself, it does alter the time to 
maximum drug effect [3, 8]. Generally speaking, most orally 
administered drugs (like digoxin) are not required to be al-
tered on the basis of age related changes in gastrointestinal 
function [8]. A number of studies have shown factors con-
tributing to absorption are generally not physiological 
changes but rather to various disease states [11]. 
Distribution 
  Drug distribution in the older person can vary due to 
changes in body composition and critical organ perfusion 
(due to reduced cardiac output and increased peripheral vas-
cular resistance) [3, 8]. The latter will also affect metabolism 
and elimination with decreased liver and kidney perfusion. 
The reduction in lean body mass in older people (as much as 
19%) will cause an elevation in drug concentrations in mus-
cles for drugs distributed in that manner (eg. digoxin) [8,14]. 
The older body also sees an increase of up to 20-40% in the 
relative fat composition (adipose tissue) independently of 
obesity and, despite the increase in fat, older people have a 
marked decrease in water content of the body of 10-15% [8, 
9, 14]. The effects of these changes on drug distribution will 
largely depend on the lipid or water solubility nature of the 
drug [8] and its metabolites. Water soluble drugs (like di-
goxin) will show a small volume of distribution (V), in-
creased plasma concentrations with reduced total body water 
and, thus, accommodation needs to be made in reducing 
loading doses [8,11,14]. Conversely, lipid soluble drugs, will 
have a larger volume of distribution and, thus, a longer half 
life [11]. The half life of water soluble drugs does not reduce 
because of the concomitant reduced renal clearance. From 
the equation below, it is clear that a reduction in V in older 
patients with concomitant reduction in renal clearance will 
cancel one another out while the renal reduction potentiates 
the effects of increased V on half life. A 10% decrease in 
blood albumin concentration has the effect of increasing the 
unbound fraction of the drug by a corresponding 10% [9].  
 T 1/2 = [0.693 x V] / renal clearance 
Metabolism 
  The vast majority of drug metabolism occurs in the liver 
with minor contributions from the kidney and lung [8]. The 
capacity of the liver to metabolise drugs decreases with age 
[6]. The 35-40% reduction in hepatic perfusion in the elderly 
has a significant impact on drug delivery to the liver and 
subsequent rate of metabolism [8, 12, 13]. Liver size can be 
reduced by about 24-35% with age [13]. One major influ-
ence is the reduced first pass metabolism of orally absorbed 
lipid soluble drugs which can significantly increase drug 
bioavailability [8]. Conversely, prodrugs that require me-
tabolism for activation may show decreased or delayed 
bioavailability [11]. Digoxin is not strongly influenced by 
first pass metabolism or hepatic metabolism. While no sig-
nificant decrease occurs in phase II metabolism, there is a 
decrease in clearance of drugs metabolised by phase I path-
ways [9]. Furthermore, the decreased capacity (up to 60%) of 
the liver to metabolise drugs for elimination can increase 
plasma concentrations and prolong biological half lives of 
drugs [8]. It has been recently reported that age related renal 
dysfunction contributes to decreased liver metabolism of 
drugs in older people [11]. Finally, the reduction in first pass 
metabolism and decreased liver capacity to manage toxins 
contribute to an increase in adverse effects in the elderly. 
Elimination 
  For water soluble drugs, like digoxin, elimination is 
solely or primarily via renal excretion [8, 9, 11]. In the eld-
erly (compared to young adults), the kidneys can show a 
20% reduction in size, 30% reduction in glomeruli function 
(elimination of drugs relates to glomeruli filtration rate), and 
as much as 50% reduction in normal renal capacity [8]. This 
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renal disease [3, 8]. Renal excretion of drugs declines with 
age so the elderly should be managed as though they have 
renal insufficiency [6, 14]. This is particularly important for 
drugs with a narrow therapeutic index, like digoxin, because 
it increases the likelihood of serious toxicity [11]. 
  While plasma creatinine levels are a poor indicator of 
renal function, creatinine clearance rates can be used to ac-
commodate loading and continuing drug doses in the elderly 
using dose corrections like the Cockcroft and Gault equation 
[8, 9]. This is essential for drugs that are highly toxic and 
which have a narrow therapeutic range like digoxin [8] and 
will be discussed in more detail below. But it is also very 
important to consider the effects of acute illness in the eld-
erly that can cause a very rapid change in renal function and, 
for example, see a stable drug regime rapidly degenerate into 
toxicity following an acute illness (eg. chest infection) [8].  
Compliance and Concordance 
 Compliance is simply defined as the extent to which a 
patient adheres to the instructions provided for a medication 
[15].  Concordance  is a variation on this concept that   
accommodates a negotiation of the instructions between   
prescriber and patient to develop a medication regime that 
suits the patient and offers therapeutic benefit [10]. Clearly 
the concept of concordance is aimed at addressing perceived 
issues in compliance. Perhaps the perception that the elderly 
are less compliant with medications actually relates more to 
medication errors than deliberate lack of compliance. Indeed, 
as few as 18% of the elderly in one study had compliance 
related problems with their medication while as many as 
50% of the elderly make errors in their medications [15].  
  Using digoxin as an example, compliance can have sev-
eral significant effects. Firstly, lack of compliance can result 
in a reduced therapeutic effect which may be difficult to dif-
ferentiate from disease progression. Secondly, the dose re-
gime may be changed (increased dose) if compliance is not 
identified as being problematic. Improved compliance after 
dose adjustment following a period of poor compliance 
could result in toxicity.  
Polypharmacy 
  Polypharmacy is very important in the elderly because it 
relates to the relationship between the greater number of 
medications taken (typically high in the elderly) and the in-
creased risk of drug interaction, decreased compliance and 
increased medication errors [9,13,15-17]. Indeed, medication 
errors increase 15 fold with an increase in medications from 
1 to 4 [15]. Polypharmacy is defined by five or more pre-
scription medications which has an incidence of 20-40% in 
the over 70 age group [9]. Older patients are frequently pre-
scribed multiple drugs which make them susceptible to drug-
drug interactions [9, 16-19]. Moreover, older people take 
more drugs with a narrow therapeutic index, increasing the 
risk of adverse reactions and drug interactions [16]. Unfortu-
nately, they are also less capable of coping with reaction and 
interactions due to co-morbidity and altered pharmacokinetics 
[16, 17].  
DIGOXIN 
  Cardiac glycosides come from foxglove (digitalis) and 
related plants [20, 21] and have been used medicinally (or as 
a poison) since 1500BC [22]. The digitalis leaf was origi-
nally reported (1785) for its role as a diuretic although its 
influence on cardiac parameters was noted [22, 23]. It was 
not until the second half of the 19
th century that the effects of 
digitalis glycosides on heart contraction were obvious [23]. 
It was only approved by the Food and Drug Administration 
(FDA in USA) for use in heart failure in 1998 [24]. 
  The mechanism of action of cardiac glycosides is gener-
ally the same with only minor pharmacokinetic differences 
between individual agents (eg. digoxin, digitoxin and   
oubain) [25]. Digoxin remains the most widely used cardiac 
glycoside (digitalis glycoside) despite the emergence of 
newer agents because it has few side effects when appropri-
ate dosing is guided by serum concentrations and because it 
does not increase long term mortality [19, 21, 22, 24,25].  
  Digoxin is incompletely absorbed (oral dose) and has   
a substantial fraction cleared by kidneys [4] with 70-85% 
excreted in urine unchanged [22, 23, 25]. The bioavailability 
of digoxin varies from 50% to more than 90% of the oral 
dose [4, 23, 25] although this increases for gelatin capsules 
to nearly 100% (intravenous is assumed to be 100%) [4, 25]. 
  Digoxin doses are typically 0.01-0.02 mg/kg for loading 
doses and then 0.125-0.25 mg/day for maintenance [4,24] 
and plasma concentrations of 1-2ug/L are considered to be 
the limits of the therapeutic range [4, 23] but this has been 
revised recently to 0.5-1 ug/L for congestive heart failure [4]. 
The half life of digoxin is 1.5-2 days (36-44 hours) although 
this becomes prolonged in renal dysfunction [4, 20-23, 25, 
26]. Digoxin has a volume of distribution of about 7.3 L/kg 
but this decreases in renal disease and hypothyroidism   
(increases in hyperthyroidism) [4].  
  Oral digoxin follows a two compartment model (Fig. 1); 
compartment one (small volume) being plasma and rapidly 
equilibrating tissues and compartment two (large volume) 
being the more slowly equilibrating tissues [4]. Concentra-
tions in heart, liver and skeletal muscle tends to be higher 
than plasma concentrations [25] and 20-30% remains plasma 
bound [22, 23, 25]. Since cardiac effects are associated with 
the larger volume, plasma concentrations are not an accurate 
reflection of pharmacologic effects until there is equilibrium 
between both compartments (at least 6 hours post oral dose) 
[4]. Nonetheless, the distribution half life of 35 min, onset  
of action (oral) of 30-120 min, and time to peak action of  
6-8 hours (oral) means that pharmacological effects can   
be seen well before equilibrium [4]. The ideal time to   
sample is 7-14 days post commencement of maintenance 
regime [4].  
  Digoxin has a narrow therapeutic index [1, 23, 25] so 
small variations in plasma concentration may readily result 
in toxic or sub therapeutic concentrations. Thus, consistency 
in bioavailability is important. Moreover, toxic symptoms 
can be evident with normal digoxin concentrations [25]. 
Doses should be individualised based on renal function in 
the first instance and modified based on response and plasma 
concentrations [25]; this is more important in older people. 
Pharmacologic Actions of Digoxin  
  There are numerous actions of digoxin on the heart; posi-
tive inotropism (increased contraction force), negative dro-
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lar node), and negative chronotropism (decreased heart rate) 
[20-23, 25, 26]. The inotropic action is due to digoxin inhib-
iting the sodium-potassium adenosine triphosphatase enzyme 
(Na
+-K
+-ATPase) which interferes with the active transport 
of sodium and potassium across the cell membrane [20-23, 
25, 26]. This, in turn, elevates intracellular sodium, increas-
ing calcium availability to produce a more forceful myocar-
dial contraction [20-23, 25, 26]. Chronotropic effects relate 
to the action of digoxin on automaticity, the ability of the 
heart to initiate impulses with external stimuli [20, 21, 23, 
25, 26]. Therapeutic plasma concentrations of digoxin de-
crease automaticity while toxic doses can have the opposite 
effect and increase automaticity [20, 21, 23, 25, 26]. Dromo-
tropic effects relate to the action of digoxin on reducing con-
duction velocity (directly through atrioventricular node and 
indirectly through vagal action) and prolonged refractory 
period [20, 21, 23, 25, 26].  
  There are also potential benefits of digoxin in the aging 
patient. Laudisio et al. [27] reported cognitive improvement 
in patients treated with digoxin. Importantly, cognitive dys-
function is a common co-morbidity in heart failure patients 
[27, 28]. The cognitive improvement in digoxin therapy re-
lates to the role endogenous cerebral digoxin plays in neu-
ronal sodium dependent transport of calcium [27]. The study 
involved more than 1100 patients with heart failure and 
showed cognitive improvement in 25% of digoxin patients 
and only 16% of non digoxin patients (P < 0.001). In those 
without heart failure (more than 2400), digoxin improved 
cognition in 23% compared to just 17% in those untreated (P 
< 0.001). The investigators corrected for confounders and 
reported an odds ratio for improving cognition of 1.7 (95% 
confidence interval of 1.2 to 2.4) for patients with heart fail-
ure but only 1.1 (95% CI of 1.0 to 1.3) for those without 
heart failure. Thus, digoxin therapy appears to selectively 
improve cognitive performance among older patients with 
heart failure. 
DIGOXIN AND AGING 
  Despite its narrow therapeutic index and potential fatal 
toxicity, particularly in the elderly, digoxin is widely used in 
the management of congestive heart failure and arrhythmia 
[17, 29, 30]. Not surprisingly given the incidence and preva-
lence of heart failure in the elderly (80%), digoxin is one of 
the most frequently prescribed medications in the over 65 
year population [10]. Given population aging (relative and 
absolute) one might expect digoxin use to further increase in 
older patients [19]. Generally, digoxin is combined with diu-
retic therapy to reduce the symptoms of heart failure and to 
increase exercise capability [10]. Unfortunately, digoxin is 
associated with a significant increase in hospitalisations and 
mortality amongst the elderly [10]. Digoxin toxicity is com-
mon in the elderly [10, 19, 30] and relates to a number of 
factors [10, 30]: 
•  Reduction in lean body mass, 
•  Decreased GFR, 
•  Decreased muscle mass, 
•  Diuretic induced potassium loss, 
•  Drug interactions, and 
•  Co-morbidity. 
  Aging results in prolonged elimination half life and de-
creased volume of distribution for digoxin [3]. A recent 
examination of more than 1000 nursing home residents in 
Canada showed that 32% of elderly heart failure patients   
are treated with digoxin, 80% of those received doses   
higher than recommended, serum digoxin levels were higher 
than toxic levels in 30% of patients, and 26% had other 
medications known to be high risk of digoxin interaction 
prescribed [29].  
  The most important age related change is that of deterio-
ration of renal function and this is especially true for digoxin 
where poorer renal excretion demands lower dosage to avoid 
toxicity [17]. This is reflected in some early research in   
normal young and old populations [31]. Using the two   
compartment model described above, the transfer constant 
from small to large compartments was increased, elimination 
was decreased and both of the compartmental volumes of 
distribution reduced. Fig. (2) provides an overview of the 
two compartment model for digoxin in older people and the 
two compartments.  
 Ewy  et al. [32] reported digoxin clearance of 53 
ml/min/1.73m
2 in older (73-81 years) men and 83 
ml/min/1.73m
2 in younger men (20-33 years). In a compari-
son of the pharmacokinetics of digoxin in young (34-61 
years) and older (72-91 years) people, Cusack et al. [33] 
reported a longer biological half life (37 to 70 hours), longer 
bioavailability (90 to 145 nmol/ml/hr), lower absorption 
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(84% to 76%), decreased volume of distribution (5.3 to 4.1 
L/Kg) and slower plasma clearance (106 to 37 ml/min) for 
the older cohort.  
  The symptoms of digoxin toxicity in the elderly are pro-
tean with the more common features including anorexia, 
cognitive changes, hazy vision, and arrhythmia [3, 25]. The 
latter three are not typical of digoxin toxicity in younger 
populations (anorexia and vomiting) and are consistent with 
numerous other physiological or pathological process in   
the elderly (poor specificity) making diagnosis of toxicity 
difficult [10, 19, 30].  
  Serum digoxin concentrations are a good marker for tox-
icity but should be interpreted with heavy weighting on 
clinical judgement because serum concentrations are not 
always a good indicator of toxicity [30]. This partly relates 
to the wide variety of co-morbid conditions and medications 
that can interfere with the reliability of the serum measure-
ment of digoxin; factors more prevalent in the elderly. With 
reference to the two compartment model, serum concentra-
tions reflect the small volume while the pharmacologic ef-
fects and toxicity are associated with the larger volume. 
Thus, it is particularly important that equilibrium between 
the two compartments is reached before serum concentra-
tions are measured. The time to equilibrium can be variable 
and in the elderly it can be delayed. Serum digoxin concen-
trations, then, may be less reliable for up to several weeks 
after commencement of digoxin therapy or indeed a change 
in dosage making assessment of both response to treatment 
and toxicity in this window difficult. Moreover, low serum 
concentrations are known to present difficulties in assay. 
Despite that limitation, the sympatholytic effects of digoxin 
can be achieved at concentrations well below those required 
for a positively inotropic effect [26]. In the elderly, increased 
sensitivity to digoxin may lead to inotropic effects at low 
concentrations. Furthermore, in older patients (60+ years) 
dosages based on the Cockcroft-Gault equation do not pre-
dict serum concentrations [9]. This, the tool designed to 
modify digoxin dosage to accommodate the alterations asso-
ciated with aging, are not reliably informed by serum assays. 
This reflects the lack of ability of the serum concentration to 
predict the complex pharmacokinetic and pharmacodynamic 
behaviour in the elderly.  
CONCLUSION 
  Digoxin remains a widely used pharmacologic agent in 
clinical practice, and is often prescribed among the elderly 
patients. Aging is an ongoing process that culminates in 
structural and functional changes in older populations and 
these changes have marked affects on critical organ systems. 
Reduced homeostatic capacity and reduced functional   
reserve have significant pharmacokinetic implications.   
Reduced functional reserve increases the vulnerability of 
older people to disease and drug toxicity. Aging leads to 
changes in body composition which, combined with de-
creased renal function and volume of distribution, prolongs 
the plasma elimination of digoxin and increases bioavailabil-
ity. Increased risk of pharmacokinetic toxicity is exacerbated 
by pharmacodynamic increases in digoxin sensitivity. An 
intimate understanding of digoxin pharmacokinetics, particu-
larly in the older person, will not only improve the quality  
of prescribing in this cohort, but will also extend advantage 
to the patient; improved therapeutic outcomes, improved 
compliance, reduced morbidity and improved quality of   
life. Specific recommendations for digoxin use in the elderly 
include: 
•  minimise the total number of medications, 
•  discontinue if no benefit is established, 
•  due consideration to drug-drug interactions and the ef-
fects of co-morbidity, 
•  undertake regular medication reviews and capitalise on 
therapeutic drug monitoring, 
•  due consideration for pharmacokinetics,  
•  employ a dose form that will maximise concordance, 
•  start doses low and escalate slowly. 
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  While digitalis has been used therapeutically for more 
than 200 years, ACE inhibitors combined with a diuretic are 
the current first-line therapy for the management of heart 
failure. Nonetheless, digoxin has an important role in pa-
tients who do not respond to these medications. Digoxin has 
a particularly important role in older sufferers of heart failure 
because it reduces the number of hospital admissions associ-
ated with escalation of symptoms. This, in conjunction with 
the increased incidence of heart failure in older people and 
the aging population, mean the digoxin will continue to be 
an important and frequently prescribed medication in older 
people. In the elderly, special consideration and dispensation 
needs to be applied for digoxin’s narrow therapeutic index, 
co-morbid diseases, polypharmacy and altered pharmacoki-
netics to minimise toxicity and sub-optimal therapy. 
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